Phenobarbital for the treatment of epilepsy in the 21st century: A critical review

Epilepsia

Volumn 45, Issue 9, 2004, Pages 1141-1149

  Kwan, Patrick ^a   Brodie, Martin J ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORAMPHENICOL; DEXTROPROPOXYPHENE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE;

AFFECT; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONNECTIVE TISSUE DISEASE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DUPUYTREN CONTRACTURE; EPILEPSY; FOLIC ACID DEFICIENCY; FROZEN SHOULDER; HUMAN; INDUSTRIALIZATION; LIVER TOXICITY; MEGALOBLASTIC ANEMIA; META ANALYSIS; MOOD DISORDER; NEUROTOXICITY; OSTEOMALACIA; OUTCOMES RESEARCH; PORPHYRIA; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; SEDATION; SIDE EFFECT; TERATOGENICITY;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG COSTS; EPILEPSY; FEMALE; HUMANS; INFANT, NEWBORN; MALE; META-ANALYSIS; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PHENOBARBITAL; PHENYTOIN; RANDOMIZED CONTROLLED TRIALS; STATUS EPILEPTICUS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 4544312379     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2004.12704.x     Document Type: Review

References (82)

1. Hauptmann A. Luminal bei Epilepsie. Munch Med Wochenschr 1912;59:1907-9.
2. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000;356:323-9.
3. World Health Organization. Initiative of support to people with epilepsy. Geneva: WHO, 1990.
4. Baldy-Moulinier M, Covanis A, D'Urso S, et al. Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. Seizure 1998;7:513-20.
5. Musicco M, Beghi E, Solari A, et al. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology 1997;49:991-8.
6. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
7. Kale R. The treatment gap, Epilepsia 2002;43(suppl 6):31-3.
8. De Boer HM. "Out of the Shadows": a global campaign against epilepsy, Epilepsia 2002;43(suppl 6):7-8.
9. A receptor channel of mouse spinal neurones in culture. J Physiol 1989;417:483-500.
10. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42:223-86.
11. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of γ-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989;25:213-20.
12. A receptors by barbiturates in cultured rat hippocampal neurons. J Physiol 1996;497:509-22.
13. Anderson GD. Phenobarbital and other barbiturates: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drug. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:596-603.
14. Nelson E, Powell JR, Conrad K, et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol 1982;22:141-8.
15. Wilensky AJ, Friel PN, Levy RH, et al. Kinetics of phenobarbital in normal subjects and epileptic patients. Eur J Clin Pharmacol 1982;23:87-92.
16. Theodore WH, Porter RJ, Raubertas RF. Seizures during barbiturate withdrawal: relation to blood level. Ann Neurol 1987;22:644-7.
17. Coulter DL. Withdrawal of barbiturate anticonvulsant drugs: prospective controlled study. Am J Ment Retard 1988;93:320-7.
18. Chadwick D. Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study. Brain 1999;122:441-8.
19. Bernus I, Dickinson RG, Hooper WD, et al. Urinary excretion of phenobarbitone and its metabolites in chronically treated patients. Eur J Clin Pharmacol 1994;46:473-5.
20. Hargraves JA, Howald WN, Racha JK, et al. Identification of enzymes responsible for the metabolism of phenobarbital [Abstract]. Int Soc Stud Xenobiot Proc 1996;10:259.
21. Ball S, Borman N. Pharmacogenetics and drug metabolism. Nat Biotech 1998;16:S4-5.
22. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. TIPS 2001;22:298-305.
23. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995;36(suppl 5):S8-13.
24. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63.
25. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone: pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 2000;55:821-5.
26. Hadama A, Ieiri I, Morita T, et al. P-hydroxylation of phenobarbital: relationship to (S)- mephenytoin hydroxylation (CYP2C19) polymorphism. Ther Drug Monit 2001;23:115-8.
27. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16:197-201.
28. Potschka H, Fedrowitz M, Löscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002;327:173-6.
29. Sills GJ, Kwan P, Butler E, et al. P-glycoprotein mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002;3:427-32.
30. Potschka H, Fedrowitz M, Löscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003;306:124-31.
31. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 2000;97:3473-8.
32. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001;11:7-21.
33. Runge D, Kohler C, Kostrubsky VE, et al. Induction of cytochrome P450 (CUP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 2000;273:331-41.
34. Seegers U, Potschka H, Loscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 2002;451:149-55.
35. Patsalos PN, Fröscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-85.
36. Leeder JS. Phenobarbital and other barbiturates: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS et al., eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:504-13.
37. Patel IH, Levy RH, Cutler RE. Phenobarbital-valproic acid interaction. Clin Pharmacol Ther 1980;27:515-21.
38. Bernus I, Dickinson G, Hooper WD, et al. Inhibition of phenobarbitone N- glucosidation by valproate. Br J Clin Pharmacol 1994;38:411-6.
39. Bruni J, Wilder BJ, Perschalski RJ, et al. Valproic acid and plasma levels of phenobarbital. Neurology 1980;80:94-7.
40. Hansen BS, Dam M, Brandt J, et al. Influence of dextro-propoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man. Acta Neurol Scand 1980;61:357-67.
41. Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967;19:317-66.
42. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-63.
43. Wei P, Zhang J, Egan-Hafley M, et al. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000;407:920-3.
44. Zelko I, Negishi M. Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes. Biochem Biophys Res Commun 2000;277:1-6.
45. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996;334:168-75.
46. De Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347:709-13.
47. Chadwick D. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39:799-803.
48. Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003;60(suppl 4):S2-12.
49. Walker MC, Sander JWAS. Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology 1997;49:333-7.
50. Mant D. Can randomised trials inform clinical decisions about individual patients? Lancet 1999;353:743-6.
51. Pocock SJ, Elboume DR. Randomized trials or observational tribulations? N Engl J Med 2000;342:1907-9.
52. Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. Seizure 2003;12:413-43.
53. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
54. Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995;58:44-50.
55. Pal DK, Das T, Chaudhury G, et al. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351:19-23.
56. Taylor S, Tudur Smith C, Williamson PR, et al. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 2003;1.
57. Tudur Smith C, Marson AG, Williamson PR. Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev 2003;3.
58. Placencia M, Sander JW, Shorvon SD, et al. Antiepileptic drug treatment in a community health care setting in northern Ecuador: a prospective 12-month assessment. Epilepsy Res 1993;14:237-44.
59. Feksi AT, Kaamugisha J, Sander JWAS, et al. Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. Lancet 1991;337:406-9.
60. Jelik-Aall L, Rwiza HT. Prognosis of epilepsy in a rural African community: a 30-year follow-up of 164 patients in an outpatient clinic in rural Tanzania. Epilepsia 1992;33:645-50.
61. Sykes RM. Epilepsy in children in Benin City, Nigeria. Ann Trop Paediatr 2002;22:287-96.
62. Mani KS, Rangan G, Srinivas HV, et al. Epilepsy control with phenobarbital or phenytoin in rural south India: the Yelandur Study. Lancet 2001;357:1316-20.
63. Nimaga K, Desplats D, Doumbo O, et al. Treatment with phenobarbital and monitoring of epileptic patients in rural Mali. Bull WHO 2002;80:532-7.
64. Baulac M, Cramer JA, Mattson RH. Phenobarbital and other barbiturates: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:528-40.
65. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001;357:216-22.
66. Reinisch JM, Sanders SA, Mortensen EL, et al. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995;274:1518-25.
67. Camfield CS, Chaplin S, Doyle AB, et al. Side effects of phenobarbital in toddlers. J Pediatr 1979;95:361-5.
68. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. N Engl J Med 1990;322:364-9. (Erratum in N Engl J Med 1992;326:144).
69. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. N Engl J Med 1990;322:364-9. (Erratum in N Engl J Med 1992;326:144).
70. Sulzbacher S, Farwell JR, Temkin N, et al. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr 1999;38:387-94.
71. Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987;80:165-74.
72. Mitchell WG, Chavez JM. Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia 1987;28:56-60.
73. Meador KJ, Loring DW, Huh K, et al. Comparative cognitive effects of anticonvulsants. Neurology 1990;40:391-4.
74. Chen, Y-J, Kang W-M, So WC-M. Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: a psychometric and neurophysiological study. Epilepsia 1996;37:81-6.
75. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42:1255-60.
76. International Drug Price Indicator Guide. Manage Sci Health, 2003. http://erc.msh.org. Accessed 26 June 2004.
77. Sander JW. Global Campaign Against Epilepsy: overview of the demonstration projects. Epilepsia 2002;43(suppl 6):34-6.
78. Wang WZ, Wu JZ, Dai XY, et al. The prevalence and treatment gap in epilepsy in China: An ILAE/IBE/WHO study. Neurology 2003;60:1544-5.
79. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev 2003;4:937-47.
80. Siddiqui A, Kerb R, Weale, ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8.
81. Walz R, Castro RMRPS, Velasco TR, et al. Surgical outcome in mesial temporal sclerosis correlates with prion protein gene variant. Neurology 2003;61:1204-10.
82. Eadie MJ. Phenobarbital and other barbiturates. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. Vol 11. New York: Lippincott-Raven, 1997:1547-55.